NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
5.45
Dollar change
+0.05
Percentage change
0.93
%
Index- P/E6.05 EPS (ttm)0.90 Insider Own57.58% Shs Outstand225.16M Perf Week0.93%
Market Cap1.23B Forward P/E- EPS next Y-0.52 Insider Trans0.00% Shs Float95.51M Perf Month15.96%
Enterprise Value794.08M PEG- EPS next Q-0.21 Inst Own3.57% Short Float2.72% Perf Quarter90.56%
Income203.50M P/S2.14 EPS this Y-163.64% Inst Trans0.12% Short Ratio2.23 Perf Half Y74.68%
Sales574.49M P/B1.76 EPS next Y3.93% ROA26.30% Short Interest2.60M Perf YTD59.82%
Book/sh3.10 P/C2.59 EPS next 5Y- ROE34.46% 52W High5.72 -4.72% Perf Year63.66%
Cash/sh2.10 P/FCF7.69 EPS past 3/5Y- - ROIC27.75% 52W Low2.37 129.96% Perf 3Y-60.90%
Dividend Est.- EV/EBITDA2.87 Sales past 3/5Y68.16% 97.04% Gross Margin83.98% Volatility1.30% 2.90% Perf 5Y-
Dividend TTM- EV/Sales1.38 EPS Y/Y TTM168.70% Oper. Margin43.92% ATR (14)0.18 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.65 Sales Y/Y TTM799.36% Profit Margin35.42% RSI (14)65.91 Recom2.71
Dividend Gr. 3/5Y- - Current Ratio7.65 EPS Q/Q28.68% SMA205.34% Beta2.53 Target Price5.48
Payout0.00% Debt/Eq0.06 Sales Q/Q-93.00% SMA5025.29% Rel Volume0.64 Prev Close5.40
Employees983 LT Debt/Eq0.05 EarningsMay 20 BMO SMA20057.96% Avg Volume1.17M Price5.45
IPOAug 14, 2020 Option/ShortYes / Yes EPS/Sales Surpr.-25.80% -79.40% Trades Volume751,012 Change0.93%
Date Action Analyst Rating Change Price Target Change
Jun-13-25Downgrade Jefferies Buy → Hold $5
Apr-25-24Downgrade Leerink Partners Outperform → Market Perform $12 → $4
Jun-08-23Initiated SVB Securities Outperform $13
Jan-19-23Upgrade UBS Neutral → Buy $8 → $18
Jan-09-23Upgrade Jefferies Hold → Buy $9 → $21
Jan-21-22Downgrade BofA Securities Neutral → Underperform $55 → $20
Jan-18-22Initiated JMP Securities Mkt Outperform $52
Oct-22-21Initiated Deutsche Bank Hold $35
Jun-17-21Downgrade BofA Securities Buy → Neutral $50
Apr-26-21Resumed Credit Suisse Underperform
Jun-24-25 04:35PM
Jun-20-25 11:51AM
Jun-13-25 12:15PM
08:16AM
Jun-12-25 04:22PM
03:29PM Loading…
03:29PM
12:49PM
12:11PM
12:01PM
10:25AM
10:20AM
07:51AM
07:44AM
07:11AM
06:58AM
02:06PM Loading…
Jun-05-25 02:06PM
May-20-25 07:15AM
May-15-25 04:45PM
08:15AM
May-14-25 08:10AM
May-13-25 09:15AM
Apr-17-25 10:51AM
Apr-11-25 12:05PM
03:01AM
02:29AM
Apr-10-25 12:59PM
07:30AM
Apr-08-25 07:25AM
05:14AM
Apr-07-25 07:15AM
03:31PM Loading…
Apr-02-25 03:31PM
Mar-29-25 12:05PM
Mar-28-25 03:24PM
Mar-27-25 04:30PM
Mar-20-25 02:11PM
Feb-20-25 10:32AM
Feb-18-25 07:15AM
Jan-08-25 04:03PM
09:13AM
09:13AM
Jan-07-25 12:12PM
Nov-20-24 11:18AM
Nov-19-24 06:31PM
Nov-15-24 02:08AM
Nov-13-24 02:13AM
Nov-12-24 07:20AM
Nov-07-24 07:30AM
Nov-04-24 07:20AM
07:15AM
Oct-30-24 07:34AM
Oct-28-24 08:10AM
Oct-22-24 06:24PM
Oct-08-24 05:50AM
Sep-13-24 08:15AM
Sep-12-24 07:15AM
Sep-09-24 07:15AM
Aug-16-24 07:07PM
Aug-15-24 07:30AM
07:20AM
07:15AM
Aug-08-24 10:00AM
Jul-15-24 12:00PM
Jul-12-24 10:53AM
Jul-11-24 07:15AM
07:00AM
Jul-04-24 09:58PM
06:33AM
Jul-03-24 12:49PM
12:41PM
11:49AM
11:12AM
10:51AM
10:18AM
10:09AM
08:19AM
07:43AM
07:21AM
06:23AM
06:12AM
04:43AM
02:40AM
02:40AM
02:25AM
Jun-24-24 04:20PM
Jun-18-24 06:59PM
Jun-03-24 06:48PM
May-28-24 07:20AM
May-23-24 07:58PM
12:45PM
07:20AM
May-15-24 01:54PM
May-10-24 06:36AM
Apr-25-24 01:30PM
05:10AM
Apr-24-24 12:27PM
07:30AM
07:20AM
07:20AM
06:22AM
Apr-18-24 07:15AM
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mulbe in 2000 and is headquartered in Tubingen, Germany.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thaminda RamanayakeaffiliateMay 07 '25Proposed Sale3.346,98623,316May 07 12:48 PM
Myriam MendilaaffiliateJan 07 '25Proposed Sale4.9317,83988,019Jan 07 05:49 PM
Pierre KemulaaffiliateJan 07 '25Proposed Sale4.9351,523254,219Jan 07 05:45 PM
Alexander ZehnderaffiliateJan 07 '25Proposed Sale4.9326,104128,800Jan 07 05:40 PM
Malte GreuneaffiliateJan 07 '25Proposed Sale4.9321,976108,365Jan 07 05:30 PM
Pierre KemulaaffiliateSep 27 '24Proposed Sale3.0855169Sep 27 12:48 PM
Pierre KemulaaffiliateSep 25 '24Proposed Sale3.1034,000105,400Sep 25 02:19 PM